Copyright
©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8205-8211
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8205
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8205
Table 2 Comparison of changes in β2-microglobulin, glycosylated hemoglobin, and Vascular endothelial growth factor levels in the disease, healthy, and simple diabetes groups (mean ± SE)
| Group | n | β2-MG (mg/L) | HbA1c (%) | VEGF (ng/L) |
| Disease group | 107 | 4.34 ± 1.53 | 10.84 ± 1.81 | 176.69 ± 11.84 |
| Simple diabetes group | 107 | 2.56 ± 1.14 | 8.40 ± 1.24 | 137.84 ± 10.36 |
| Healthy groups | 107 | 1.11 ± 0.82 | 4.58 ± 0.95 | 109.32 ± 12.44 |
| F value | 195.518 | 558.284 | 912.281 | |
| P value | 0.000 | 0.000 | 0.000 | |
| LSD-t (disease vs simple diabetes) | 10.862 | 12.921 | 24.535 | |
| P value | 0.000 | 0.000 | 0.000 | |
| LSD-t (disease vs healthy) | 19.742 | 33.148 | 42.548 | |
| P value | 0.000 | 0.000 | 0.000 | |
| LSD-t (healthy vs simple diabetes) | 8.879 | 20.228 | 18.013 | |
| P value | 0.000 | 0.000 | 0.000 |
- Citation: Yang B, Zhao XH, Ma GB. Role of serum β2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy. World J Clin Cases 2022; 10(23): 8205-8211
- URL: https://www.wjgnet.com/2307-8960/full/v10/i23/8205.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i23.8205